NATCO Pharma announces successful completion of USFDA inspection

NATCO Pharma Limited has announced the successful completion of United States Food and Drug Administration's (USFDA) inspection of the firm's compliance to Pharmacovigilance requirements with zero observations.

NATCO's Pharmacovigilance Department, at its Corporate Office in Hyderabad, was inspected from October 30, 2023 to November 1, 2023. The Pharmacovigilance procedures of NATCO for its products marketed globally and particularly, in USA, were inspected and found to comply with USFDA's requirements.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 741.15 as compared to the previous close of Rs. 799.95. The total number of shares traded during the day was 41541 in over 3571 trades.

The stock hit an intraday high of Rs. 809.90 and intraday low of 732.05. The net turnover during the day was Rs. 31622791.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 USFDA Inspection ZeroObservations